Perspective Therapeutics, Inc. (CATX)
NYSE American · Healthcare · Medical Devices
$2.57−6.88%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $293M
- 52-week range
- $1.96 – $6.16
- 52-week change
- −20.46%
- EPS (trailing)
- −$1.33
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Net income
- −$103M
- Diluted EPS
- −$1.40
- Free cash flow
- −$95.2M
From the company’s annual report on SEC EDGAR.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.
Headquarters: Seattle, United States · 163 employees · perspectivetherapeutics.com